Suppr超能文献

治疗后 HIV-乙型肝炎合并丙型和丁型肝炎病毒感染患者中病毒相互作用的纵向评估。

Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus.

机构信息

INSERM, Paris and UMR-S707, Université Pierre et Marie Curie-Paris6, Paris, France.

出版信息

J Viral Hepat. 2010 Jan;17(1):65-76. doi: 10.1111/j.1365-2893.2009.01153.x. Epub 2009 Aug 4.

Abstract

Virological interactions of hepatitis B (HBV), hepatitis C (HCV) and hepatitis D (HDV) viruses in HIV-infected patients have been poorly characterized especially under treatment influences. Undetection rates of hepatitis viruses were longitudinally analyzed in a 3-year cohort of 308 HIV-HBV co-infected patients and compared using Generalized Estimating Equation models adjusted for age, HIV-RNA, CD4 cell-count and antiviral treatment. Chronic hepatitis co-infection in HIV-infected patients (age years, SD) was: 265 HBV (40.7, 8.2); 19 HBV-HCV (39.7, 4.1); 12 HBV-HDV (35.2, 9.9); 12 HBV-HCV-HDV (39.2, 5.2). At inclusion, treatment with lamivudine/tenofovir was not significantly different between co-infection groups. HBV suppression was significantly associated with HDV (aOR = 3.85, 95%CI 1.13-13.10, P = 0.03) and HCV tri-infection (aOR = 2.65, 95%CI 1.03-6.81, P = 0.04), but marginally associated with HIV-HBV-HCV-HDV (aOR = 2.32, 95%CI 0.94-5.74, P = 0.07). In quad-infection, lower HDV-undetectability (vs HIV-HBV-HDV, P = 0.2) and higher HCV-undetectability (vs HIV-HBV-HCV, P = 0.1) were demonstrated. The degree of HBV suppression varied between visits and co-infection groups [range of aOR during follow-up (vs HIV-HBV co-infection): HIV-HBV-HCV = 2.23-5.67, HIV-HBV-HDV = 1.53-15.17]. In treated co-infected patients, HDV expressed continuous suppression over HCV- and HBV-replications. Peaks and rebounds from undetectable hepatitis B, C and/or D viremia warrant closer follow-up in this patient population. HDV-replication was uncontrolled even with antiviral treatment.

摘要

在感染 HIV 的患者中,乙型肝炎(HBV)、丙型肝炎(HCV)和丁型肝炎(HDV)病毒的病毒学相互作用特征描述较差,尤其是在治疗影响下。在一项为期 3 年的 308 例 HIV-HBV 共感染患者队列中,对病毒未检出率进行了纵向分析,并使用广义估计方程模型进行调整,以适应年龄、HIV-RNA、CD4 细胞计数和抗病毒治疗。HIV 感染患者的慢性肝炎合并感染(年龄岁,SD)为:265 例 HBV(40.7,8.2);19 例 HBV-HCV(39.7,4.1);12 例 HBV-HDV(35.2,9.9);12 例 HBV-HCV-HDV(39.2,5.2)。纳入时,拉米夫定/替诺福韦治疗在合并感染组之间无显著差异。HBV 抑制与 HDV(优势比[aOR]=3.85,95%CI 1.13-13.10,P=0.03)和 HCV 三重感染(aOR=2.65,95%CI 1.03-6.81,P=0.04)显著相关,但与 HIV-HBV-HCV-HDV 相关(aOR=2.32,95%CI 0.94-5.74,P=0.07)呈边缘相关。在四重感染中,较低的 HDV 未检出率(与 HIV-HBV-HDV 相比,P=0.2)和较高的 HCV 未检出率(与 HIV-HBV-HCV 相比,P=0.1)被证明。HBV 抑制程度在不同访视和合并感染组之间有所不同[随访期间 aOR 的范围(与 HIV-HBV 合并感染相比):HIV-HBV-HCV=2.23-5.67,HIV-HBV-HDV=1.53-15.17]。在治疗的共感染患者中,HDV 在 HCV 和 HBV 复制过程中持续表达抑制。在这种患者人群中,从乙型肝炎、丙型肝炎和/或丁型肝炎病毒血症不可检测到的峰值和反弹需要更密切的随访。即使进行抗病毒治疗,HDV 的复制也无法得到控制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验